- $177.44m
- $62.41m
- $6.39m
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- AGNC Investment, Brown & Brown, Korro Bio
Street View: Korro Bio plummets after disappointing drug trial
U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare
Korro Bio plunges on trial failure, Novo Nordisk deal halt
Brief: Korro Bio - Vineet Agarwal Announces Intention To Resign From His Position Of CFO
Korro Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Korro Bio Inc expected to post a loss of $2.56 a share - Earnings Preview
Korro Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Korro Bio Inc expected to post a loss of $2.58 a share - Earnings Preview
Brief: Korro Bio Inc - Announces 20% Workforce Reduction - SEC Filing
U.S. RESEARCH ROUNDUP- 3M, Citigroup, Nvidia
Brief: Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO
U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY
Brief: Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical Leave